Organoids refer to the artificially grown three-dimensional cultures of tissues obtained from stem cells. The organoids demonstrate similar organ functionalities to those present in various organs and have the ability to self-renew and self-organize themselves.
The rise in organoid-led medical research and various discoveries made by them which are beneficial for the treatment of various diseases are contributing significantly to the market growth and are expected to bolster the market growth during the forecast period. Also, as the prevalence of cancer around the world is increasing, the organoids are increasingly being used to understand cancer cells better and consequently find better treatments for cancer, which in turn, is anticipated to surge the organoids market growth in the coming years. Better drug testing, personalized medicine, and aspiration for creating transplantable organs in labs are also some of the factors which are expected to propel the organoids market growth during the forecast period.
The recent outbreak of the novel coronavirus disease is anticipated to positively impact the market growth to some extent. The organoids are increasingly being used during the Covid-19 pandemic to better understand the biology of the novel coronavirus and its effect on the human organs. The scientists developed mini lung organoids to study how alveolar cells respond to SARS-CoV-2 infection. These utilities of organoids in understanding the virus led to growth in the organoids market and due to successful studies, the organoids are further anticipated to propel the market growth during the forecast period.
The Organoids Market has been classified on the basis of organ, application, end-user, and geography. By Organ, the market has been classified on the basis of Liver, Brain, Lungs, Kidney, Intestine, Pancreas, and others. On the basis of Application, the segmentation has been done into Cancer research, Drug testing, Personalized medicine, Regenerative medicine, Therapeutic tools, and others. By End User, the market has been categorized into Biotechnology and Pharmaceutical Companies, Academic and Research Institutions, and Hospitals and Diagnostic Centers. Geographically, the market for Organoids has been distributed into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific.
Growing organoid-led medical research
One of the key factors supplementing the Organoids Market growth includes the rise in organoid-led research and development in the medical field to study the human organs and diseases related to them. In February 2021, a team of researchers from Stanford University showed in its study that the organoids for brain cells when grown in a lab for more than a year closely resembled the cells of human brains of newborn babies. This could make it easy for researchers to study brain studies. These recent developments in research have even led to the hope of growing transplantable human organs in labs. Cincinnati Children's Hospital Medical Center in September 2019 developed a three organoid system having the liver, pancreas, and biliary ducts. According to the researchers, the connected system can provide much more information compared to three disconnected organoids and allow more precise diagnosis and customized treatment. Also, the development is expected to lead to growing organ tissues large enough to be useful in human transplantation in the future. These new discoveries are leading to even greater implementation of organoids in medical research and hence are anticipated to bolster the market growth of organoids during the forecast period.
The rise in the use of organoids in cancer research
Organoids are increasingly being used in cancer research, which is making the use of organoids even more prominent as cancer has been growing rapidly around the world. According to the National Cancer Institute database, the prevalence of cancer has been increased by around 30% from 1973 to 2015 and is still growing. In India, the Indian Council of Medical Research (ICMR) and the National Centre for Disease Informatics and Research (NCDIR) have estimated in August 2020 that there will be a rise in cancer cases in India by 12% in the coming five years. The medical sector around the world has been doing various studies and researches to provide a solution for this problem. The organoids provide a better way to study the cancer cells more properly and hence aid in finding a solution. Hans Clevers (Hubrecht Institute) in April 2021 developed the first organoid model for cervical cancer by deriving tissues from patients. The institute collaborated with the UMC Utrecht, Princess Maxima Center for pediatric oncology, and the Netherlands Cancer Institute and stated that the model can be used to study cervical cancer based on the study of human papillomavirus (HPV) through the model. The Nature Review Cancer journal published in United States National Library of Medicine, National Institutes of Health, in July 2018 stated that the organoid-led cancer research has opened new paths for the development of novel treatment regimens for patients with cancer. It also stated that organoids are grown from patient-derived healthy and tumor tissues can enable patient-specific drug testing and personalized treatments for cancer patients. These developments are anticipated to be a major driver propelling the growth of the organoids market during the assessment period.
North America to hold a prominent share in the market
Geographically, the North American region is anticipated to hold a significant share in the market owing to the high healthcare expenditures by governments of countries like the United States and Canada, which leads to the fast adoption of new technologies in the medical industry in the region The European region is anticipated to witness remarkable growth due to rising investments in the organoid and modern healthcare sector.
Prominent/major key market players in the Organoids Market include STEMCELL Technologies, Inc., Cellesce Ltd., and Hubrecht Organoid Technology among others. The players in the Organoids Market are implementing various growth strategies to gain a competitive advantage over its competitors in this market. Major market players in the market have been covered along with their relative competitive strategies and the report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered along with the recent deals and investments of these important players in the Organoids Market.
|Forecast Unit (Value)||USD Billion|
|Segments covered||Organ, Application, End-User, And Geography|
|Regions covered||North America, South America, Europe, Asia Pacific|
|Companies covered||STEMCELL Technologies, Inc., Cellesce Ltd., Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences), Merck KGgA|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What is the base year considered in the organoid technology market report?
A1. 2019 has been taken as the base year in the organoid technology market report.
Q2. How is the organoid technology market segmented?
A2. The organoid technology market has been segmented by organ, application, end-user, and geography.
Q3. Who are the major players in the organoid technology market?
A3. Prominent/major key market players in the organoids market include STEMCELL Technologies, Inc., Cellesce Ltd., and Hubrecht Organoid Technology among others.
Q4. What factors are anticipated to drive the organoid technology market growth?
A4. The rise in organoid-led medical research and various discoveries made by them which are beneficial for the treatment of various diseases are contributing significantly to the organoid market growth.
Q5. Which region holds the largest market share in the organoid technology market?
A5. The North American region is anticipated to hold a significant share in the organoid technology market owing to the high healthcare expenditures by governments of countries like the United States and Canada.